Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
United States
University of Alabama at Birmingham, Birmingham, Alabama City of Hope Comprehensive Cancer Center, Duarte, California UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco, California Stanford University Medical Center, Stanford, California Colorado Blood Cancer Institute, Denver, Colorado Yale Cancer Center, New Haven, Connecticut Moffitt Cancer Center, Tampa, Florida Dana-Farber Cancer Institute, Boston, Massachusetts Icahn School of Medicine at Mount Sinai, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York Local Institution - 0008, Nashville, Tennessee Tennessee Oncology, Nashville, Tennessee Swedish Medical Center, Seattle, Washington France
Hôpital Saint-Louis, Paris Germany
Universitaetsklinikum Koeln, Cologne Universitaetsklinikum Heidelberg, Heidelberg Universitaetsklinikum Wuerzburg, Würzburg Spain
Clinica Universidad de Navarra, Pamplona, Navarre Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca